Abbott has achieved a milestone in cardiac care with the successful completion of the world's first-in-human leadless left bundle branch area pacing (LBBAP) procedures using its investigational AVEIR Conduction System Pacing (CSP) leadless pacemaker. This breakthrough, part of a feasibility study conducted in 2024, integrates conduction system pacing and leadless pacemaker technology for the first time. The AVEIR CSP system directly targets the left bundle branch area to mimic the heart's natural rhythm, offering an innovative solution for patients with slower-than-normal heart rates. Led by experts including Professor Petr Neužil of Na Homolce Hospital and Dr. Vivek Reddy of Mount Sinai Hospital, this study marks a transformative advancement in physiological pacing.
Building on the success of its FDA-approved AVEIR dual chamber (DR) leadless pacemaker system, Abbott continues to innovate in cardiac rhythm management. The AVEIR DR system utilizes i2i technology for synchronized pacing between co-implanted pacemakers, eliminating the need for traditional leads and pulse generators. Abbott's groundbreaking work has earned the AVEIR CSP system Breakthrough Device Designation from the FDA, underscoring its potential to revolutionize care for patients with life-threatening arrhythmias. As a global healthcare leader, Abbott remains committed to advancing medical technology to improve lives worldwide.
